ALAR vs BCYC

For growth investors, Bicycle Therapeutics plc (BCYC) is the stronger pick with 105.

8% revenue growth year-over-year, versus 20. 9% for Alarum Technologies Ltd. (ALAR). Alarum Technologies Ltd. (ALAR) offers the better valuation at 9. 4x trailing P/E, making it the more compelling value choice. Analysts rate Bicycle Therapeutics plc (BCYC) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Alarum Technologies Ltd.

(ALAR) delivered a total return of -36. 6%, compared to -84. 6% for Bicycle Therapeutics plc (BCYC). Over 10 years, the gap is even starker: BCYC returned -59. 3% versus ALAR's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bicycle Therapeutics plc (BCYC) is the lower-risk stock at 1.

65β versus Alarum Technologies Ltd. 's 2. 01β — meaning ALAR is approximately 22% more volatile than BCYC relative to the S&P 500. On balance sheet safety, Bicycle Therapeutics plc (BCYC) carries a lower debt/equity ratio of 3% versus 6% for Alarum Technologies Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bicycle Therapeutics plc (BCYC) is pulling ahead at 105.

8% versus 20. 9% for Alarum Technologies Ltd. (ALAR). On earnings-per-share growth, the picture is similar: Alarum Technologies Ltd. grew EPS 160. 7% year-over-year, compared to -9. 0% for Bicycle Therapeutics plc. Over a 3-year CAGR, BCYC leads at 71. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alarum Technologies Ltd.

(ALAR) is the more profitable company, earning 18. 2% net margin versus -301. 7% for Bicycle Therapeutics plc — meaning it keeps 18. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALAR leads at 21. 1% versus -341. 3% for BCYC. At the gross margin level — before operating expenses — BCYC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Bicycle Therapeutics plc (BCYC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

Alarum Technologies Ltd. (ALAR) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BCYC: -59. 3%, ALAR: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ALAR (Technology) and BCYC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.